Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.33 |
| ▸ | KDM4A | O75164 | 2/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20550782 | 0.95 | KDM4C (0.39) | KDM5BKDM5AKDM2BNPSR1KDM4C | |
| SCHEMBL17503779 | 0.91 | KDM5B (0.41) | KDM5BKDM5AKDM2BKDM4CKDM4A | |
| SCHEMBL17503804 | 0.91 | KDM4C (0.41) | KDM5BKDM5AKDM2BKDM4CKDM4A | |
| SCHEMBL17503744 | 0.88 | KDM2B (0.39) | KDM5BKDM5AKDM2BKDM4CKDM4A | |
| SCHEMBL17503762 | 0.85 | KDM5A (0.49) | KDM5BKDM5AKDM2BKDM4CKDM4A | |
| SCHEMBL16128867 | 0.78 | KDM5A (0.34) | KDM5BKDM5AKDM2BKDM4CKDM4A | |
| SCHEMBL17503843 | 0.73 | KDM4C (0.41) | KDM5BKDM5AKDM2BKDM4CKDM4A | |
| SCHEMBL16034190 | 0.72 | KDM5A (0.71) | KDM5BKDM5AKDM2BKDM4CKDM4A | |
| SCHEMBL17503689 | 0.71 | CYP2D6 (0.38) | KDM5BKDM5AKDM4CKDM4AADAMTS5 | |
| SCHEMBL16075682 | 0.70 | KDM5B (0.55) | KDM5BKDM5AKDM2BKDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2970211-B1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM5B 6/4885KDM5A 4/4885KDM2B 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.